Sarcomatoid Mesothelioma

Fact Checked

Sarcomatoid mesothelioma is a tumor composed of sarcomatoid cells. Sarcomatoid cells spread quickly and are about 10% to 20% of all mesothelioma cases. Sarcomatoid mesothelioma is a more treatment-resistant type of mesothelioma compared to epithelial or biphasic mesothelioma.

Free Sarcomatoid Mesothelioma Guide
Patient Advocate Karen Selby explains sarcomatoid mesothelioma.
Patient Advocate Karen Selby explains sarcomatoid mesothelioma.

Sarcomatoid: The Most Aggressive Mesothelioma Cell Type

Sarcomatoid mesothelioma is sometimes referred to as sarcomatous, spindle or diffuse malignant fibrous mesothelioma.

Spindle refers to the appearance of the cells when viewed under a microscope. They are long and spindle-shaped.

Sarcomatoid mesothelioma cell

Diffuse and fibrous describes how the tumors appear within the pleural membrane that surrounds the lungs and lines the chest cavity. Sarcomatoid tumors can merge to form a sheet-like, fibrous mass on the pleural membrane.

It is the least common of all of the types of mesothelioma. Compared to epithelial and biphasic types of mesothelioma, it is also the most aggressive and resistant to treatment.

Nearly all sarcomatoid mesotheliomas are pleural. Fewer than 30 documented cases have occurred in people with peritoneal mesothelioma.

Diagnosis of Sarcomatoid Mesothelioma

Mesothelioma is easily misdiagnosed because signs of the disease mimic other, less serious conditions.

A 2018 study published in Lung Cancer describes a new approach for more accurate sarcomatoid mesothelioma diagnosis. Tests for the BAP1 and MTAP genes were 100% accurate for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.

However, most doctors still use the traditional methods of determining a diagnosis.

Once a doctor has ruled out other causes of ongoing symptoms, they will order imaging studies such as X-rays, a CT scan or an MRI. These tests reveal abnormalities in the chest, but they do not reveal exactly what is causing these changes.

If your imaging studies suggest cancer, your doctor will refer you to a surgeon to retrieve tumor tissue through a biopsy. Surgeons often use thoroscopy or video-assisted thoracic surgery procedures to biopsy mesothelioma. These techniques can increase the chances of an accurate diagnosis.

Seeking a mesothelioma specialty team is important, too, because this group will include pathologists skilled in this diagnosis.

Common Misdiagnoses for Sarcomatoid Mesothelioma

Sarcomatoid cells present an extra level of difficulty to obtaining an accurate diagnosis.

They are easily misdiagnosed as other cancers and some noncancer conditions.

  • Pleural liposarcoma
  • Fibrous pleurisy or pleuritis
  • Sarcoma or fibrosarcoma
  • Malignant fibrous histiocytoma (also called undifferentiated pleomorphic sarcoma)
  • Localized fibrous tumors
  • Metastasized renal cell carcinoma
  • Solitary fibrous tumor of the pleura (hemangiopericytoma)
Mesothelioma Nutrition Guide

Find a Sarcomatoid Mesothelioma Doctor Near You

We'll help you or a loved one find the most qualified mesothelioma specialists and treatment facilities in your area.

Find a Doctor Near You

Symptoms of Sarcomatoid Mesothelioma

Most patients experience nonspecific symptoms such as cough, shortness of breath and chest pain prior to diagnosis.

As the disease progresses, symptoms become more serious.

  • Shortness of breath
  • Prolonged hoarseness
  • Persistent cough
  • Coughing up blood
  • Low blood oxygen levels
  • Anemia (low iron)
  • Weight loss and weakness
  • Abdominal “fullness”
  • Lack of appetite, anorexia and nausea
  • Fatigue and extreme tiredness

Sarcomatoid Mesothelioma Treatment

A 2019 study published in The Annals of Thoracic Surgery found many patients do not receive treatment consistent with national guidelines on the management of malignant pleural mesothelioma.

The most important way to ensure you receive optimal care is to be treated at a cancer center with experience managing this rare, asbestos-related disease.

The primary mesothelioma treatment options — surgery, chemotherapy and radiation therapy — typically are chosen based on the stage and location of the cancer, regardless of cell type.

Surgery

Surgery is challenging because sarcomatoid tumors are rigid, often spread over large areas and can grow into the chest wall.

All of these features mean surgery alone isn’t likely to be effective for complete tumor removal. in some cases, mesothelioma surgery may not be an option for patients with sarcomatoid disease.

With peritoneal tumors, the cancer can grow into or encase the soft internal organs of the abdomen.

Chemotherapy

The standard chemotherapy for treating pleural mesothelioma is a combination of Alimta (pemetrexed) plus cisplatin or carboplatin. This includes sarcomatoid cell type, which is found almost exclusively in the pleural membrane.

Radiation Therapy

Radiation therapy is not considered curative for mesothelioma. However, it can improve quality and length of life for some patients. It can be used as part of a palliative care plan to reduce symptom severity.

Mesothelioma Nutrition Guide

Free Mesothelioma Nutrition Guide

Eating right and balancing your diet while undergoing mesothelioma treatment can help ease your symptoms.

Get Free Recipes & Tips

Prognosis

The median survival for patients with sarcomatoid tumors is typically less than six months, but some patients live longer.

Patients with the lymphohistiocytoid cell subtype have survived as long as six years.

Prognosis estimates are based on past data. As treatment options improve and newer, cutting-edge therapies are employed, prognosis typically improves as well. This effect isn’t captured in current survival rate statistics.

If you are interested in a clinical trial that may improve prognosis, seek treatment at a specialty mesothelioma treatment facility.

Rare Mesothelioma Variants

Transitional Mesothelioma
This variant tends to grow and spread in ways similar to other sarcomatoid mesotheliomas. It has plump spindle-shaped cells, which help pathologists differentiate it from other cells.
Lymphohistiocytoid Mesothelioma
These tumors contains inflammatory and immune cells. Lymphohistiocytoid variant makes up less than 1% of all mesotheliomas. Some patients with this cancer have better-than-average life expectancy.
Desmoplastic Mesothelioma
This variant is a sarcomatoid subtype. It is one of the most difficult to diagnose. Half or more of the tumor shows no discernible pattern of growth. Desmoplastic type accounts for approximately 5% of all mesotheliomas.

Join Our Next Mesothelioma Support Group

Register Now

Find a Mesothelioma Clinical Trial

We Can Help

Get Help Covering Expenses

Find out How

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Reviewed by placeholder
Medical Review By

11 Cited Article Sources

  1. Espinoza-Mercado, F. et al. (2019, April 17). Disparities in Compliance with National Guidelines for the Treatment of Malignant Pleural Mesothelioma. DOI:
    Retrieved from: https://doi.org/10.1016/j.athoracsur.2019.03.052
  2. Harris, E.J.A. et al. (2019, January 16). Diagnosis of asbestos-related lung diseases.
    Retrieved from: https://doi.org/10.1080/17476348.2019.1568875
  3. Kinoshita, Y. et al. (2018, November). A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. :
    Retrieved from: https://doi.org/10.1016/j.lungcan.2018.09.019
  4. Kindler, H. et al. (2018, May 1). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
    Retrieved from: http://ascopubs.org/doi/pdf/10.1200/JCO.2017.76.6394
  5. Rossini, M. et al. (2018, April 3). New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
    Retrieved from: https://www.frontiersin.org/articles/10.3389/fonc.2018.00091/full
  6. Husain, A.N. et al. (2018, January). Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
    Retrieved from: https://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0124-RA
  7. Berg, K.B. and Churg, A. (2017, September). GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
    Retrieved from: https://www.ingentaconnect.com/content/wk/ajsp/2017/00000041/00000009/art00008
  8. Marchevsky, A.M. et al. (2017, September). The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Retrieved from: https://www.sciencedirect.com/science/article/pii/S0046817717302678
  9. Kinoshita, Y. et al. (2018, November). A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Retrieved from: https://www.lungcancerjournal.info/article/S0169-5002(18)30578-6/fulltext
  10. Pavlisko, E.N. and Roggli, V.L. (2015, November). Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases. DOI: 10.1097/PAS.0000000000000495
  11. Tischoff, I. et al. Pathohistological diagnosis and differential diagnosis. DOI: 10.1007/978-3-642-10862-4_5
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified November 8, 2019

Chat live with a patient advocate now